BlackRock Fund Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

BlackRock Fund Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$328K	Sell	2,068 -1,583	-43%	-$303K	﹤0.01%	3310
2016 Q3	$905K	Buy	3,651 +340	+10%	+$124K	﹤0.01%	3233
2016 Q2	$2.96M	Buy	3,311 +36	+1%	+$39.7K	﹤0.01%	3082
2016 Q1	$2.98M	Buy	3,275 +101	+3%	+$99.1K	﹤0.01%	2963
2015 Q4	$4.48M	Buy	3,174 +1,680	+112%	+$2.93M	﹤0.01%	2890
2015 Q3	$2.5M	Sell	1,494 -10	-0.7%	-$20.6K	﹤0.01%	3068
2015 Q2	$3.24M	Buy	1,504 +451	+43%	+$873K	﹤0.01%	3082
2015 Q1	$1.93M	Buy	1,053 +50	+5%	+$110K	﹤0.01%	3137
2014 Q4	$2.39M	Buy	+1,003	New	+$2.38M	﹤0.01%	3133

Other funds holding ELDN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock Fund Advisors's ELDN Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Eledon Pharmaceuticals (ELDN) stake by 43% in Q4 2016, selling an estimated $303K and leaving 2,068 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

BlackRock Fund Advisors first reported a position in ELDN in Q4 2014 and has held it in 9 quarters since. The position peaked at $4.48M in Q4 2015. 42 funds tracked by Wall St. Rank hold ELDN as of Q4 2016.

BlackRock Fund Advisors held 2,068 shares of Eledon Pharmaceuticals worth $328K as of Q4 2016.
BlackRock Fund Advisors sold 1,583 Eledon Pharmaceuticals shares in Q4 2016, an estimated $303K.
Eledon Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3310 holding.
BlackRock Fund Advisors first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 9 quarters since.
BlackRock Fund Advisors's Eledon Pharmaceuticals position peaked at $4.48M in Q4 2015.
42 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.